<DOC>
	<DOCNO>NCT02404519</DOCNO>
	<brief_summary>Vitamin K require activation inhibitor vascular calcification : Matrix Gla Protein ( MGP ) . In early study beneficial effect menaquinone-7 ( MK-7 ) , vitamin K2 form , observed stiffness vessel wall postmenopausal woman . It decrease circulate form inactive MGP improve vascular elasticity ( local ) aortic pulse wave velocity ( regional ) . The decrease circulate inactive MGP observe 2-3 month MK-7 supplementation effect MK-7 clinical endpoint observe within 3 year supplementation . It demonstrate several study cardiovascular risk increase decrease vitamin K intake increase level inactive MGP . In study investigator select subject high tertile circulate inactive MGP . This study group consist subject increase cardiovascular risk expect effect MK-7 clinical endpoint group measurable within 1 year supplementation .</brief_summary>
	<brief_title>Vitamin K2 Effect Vascular Stiffening Subjects With Poor Vitamin K-status</brief_title>
	<detailed_description>This study double-blind randomize placebo-controlled intervention study . In total 240 healthy men woman 40 70 year recruit province Limburg small advertisement local newspaper . Eligible participant randomize 2 study group : - Group 1 : MK-7 ( 1 tablet : MK-7 dosage 180 μg ) - Group 2 : Placebo ( 1 tablet : MK-7 dosage 0 µg ) Each group consist 120 participant . A double-blind design choose avoid occurrence bias study . After randomization , participant consume placebo MK-7 tablet daily either breakfast dinner one year . People interested participate come research laboratory VitaK screen visit ( day -14 ) . During visit , investigator check whether volunteer eligible inclusion base in- exclusion criterion . After meet inclusion criterion none exclusion criterion , volunteer assign randomization number computer-generated randomization list . A stratified block randomization perform gender , order avoid unequal distribution men woman among 2 treatment group . On-site measurement perform t=0 1 year treatment : carotid-femoral Pulse Wave Velocity ( cfPWV ; primary outcome ) echotracking common carotid artery ass vascular stiffness ( secondary outcome ) . A Whole Body scan DXA perform determine total fat lean mass participant . Blood take overnight fast period t=0 1 year measure circulate level inactive MGP . Results previous study ( NCT00642551 ) show significant change vascular characteristic , pulse wave velocity 3 year intervention period daily dosage 180 µg MK-7 240 postmenopausal woman . After 1 year MK-7 intervention inactive MGP level ( improvement vascular vitamin K status ) decrease 50 % compare placebo remain level follow 2 year intervention . Recently publish population-based study show unfavorable cardiovascular outcome mainly attributable within high quartile circulate dp-ucMGP . We expect , therefore , intervention study among preselected subject poor vascular vitamin K status ( inactive MGP level &gt; 500 pmol/L ) treatment dosage MK-7 ( i.e . 180 µg/day ) one year pronounce effect arterial stiffening pulse wave velocity .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Vitamin MK 7</mesh_term>
	<criteria>Men woman 40 70 year old Subjects body weight height accord BMI 20 35 kg/m2 Subjects Caucasian race Subject give write consent take part study Subjects circulate dpucMGP high 500 pmol/L Subjects cardiovascular disease Subjects hyperlipidaemia Subjects ( history ) metabolic gastrointestinal disease Subjects present chronic degenerative and/or inflammatory disease Use 3 unit alcohol/day Subjects receive oestrogen treatment ( woman ) Subjects use corticosteroid Subjects use oral anticoagulant subject clot disorder Subjects use vitamin K contain multivitamin supplement</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vitamin K</keyword>
	<keyword>Menaquinone-7</keyword>
	<keyword>Matrix Gla Protein</keyword>
	<keyword>Vascular stiffness</keyword>
</DOC>